Quantum Pharmics ANDA withdrawals
Executive SummaryAHP subsidiary formally notified of FDA withdrawal of 25 ANDAs via a June 19 Federal Register notice. The notice follows up on a Nov. 17 agency letter to the company informing them that the withdrawals were being initiated based on concerns raised about application data reliability and product bioinequivalence ("The Pink Sheet" Nov. 20, p. 11).
You may also be interested in...
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.